NYSEAMERICAN:OGEN - Oragenics Stock Price, Price Target & More

$1.47 -0.06 (-3.92 %)
(As of 04/26/2018 01:22 AM ET)
Previous Close$1.53
Today's Range$1.36 - $1.88
52-Week Range$0.17 - $6.80
Volume1.44 million shs
Average Volume296,127 shs
Market Capitalization$105.48 million
P/E RatioN/A
Dividend YieldN/A


Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-94.88%


Outstanding Shares6,090,000

How to Become a New Pot Stock Millionaire

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

When did Oragenics' stock split? How did Oragenics' stock split work?

Shares of Oragenics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter. View Oragenics' Earnings History.

Who are some of Oragenics' key competitors?

Who are Oragenics' key executives?

Oragenics' management team includes the folowing people:
  • Dr. Alan F. Joslyn Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 62)
  • Dr. Martin Handfield M.Sc., Ph.D., Sr. VP of Discovery Research (Age 47)
  • Dr. Guojun Nie Ph.D., Director of Process Devel.
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

Has Oragenics been receiving favorable news coverage?

Media coverage about OGEN stock has been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oragenics earned a media sentiment score of 0.09 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $1.47.

How big of a company is Oragenics?

Oragenics has a market capitalization of $105.48 million.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.

MarketBeat Community Rating for Oragenics (OGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Oragenics and other stocks. Vote "Outperform" if you believe OGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oragenics (NYSEAMERICAN:OGEN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/26/2016 forward)


Oragenics (NYSEAMERICAN:OGEN) Earnings History and Estimates Chart

Earnings by Quarter for Oragenics (NYSEAMERICAN:OGEN)

Oragenics (NYSEAMERICAN OGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.20)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.40)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.50)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.40)($0.40)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.50)ViewN/AView Earnings Details
5/16/2016Q1 2016($0.50)$0.26 millionViewN/AView Earnings Details
3/30/2016Q4 2015($0.60)$0.24 millionViewN/AView Earnings Details
11/6/2015Q3 2015($0.50)$0.33 millionViewN/AView Earnings Details
8/7/2015Q2 2015($1.70)$0.24 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.40)$0.36 millionViewN/AView Earnings Details
2/27/2015Q4 2014($0.30)$0.22 millionViewN/AView Earnings Details
11/3/2014Q3 2014($0.30)$0.20 millionViewN/AView Earnings Details
8/7/2014Q2 2014($1.00)($0.50)$0.30 millionViewN/AView Earnings Details
5/9/2014($0.90)($0.50)$0.22 millionViewN/AView Earnings Details
2/28/2014Q4 2013($0.90)($0.90)$0.44 millionViewN/AView Earnings Details
10/25/2013Q3 2013($3.40)$0.25 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.50)($0.80)$0.17 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.90)($0.60)$0.18 millionViewN/AView Earnings Details
3/22/2013Q4 2012($0.70)ViewN/AView Earnings Details
8/10/2012Q2 2012($5.20)ViewN/AView Earnings Details
5/15/2012Q1 2012($2.50)ViewN/AView Earnings Details
4/16/2012Q4 2011($3.30)ViewN/AView Earnings Details
11/14/2011Q3 2011($3.20)ViewN/AView Earnings Details
4/1/2009Q4 2008($16.00)ViewN/AView Earnings Details
11/4/2008Q3 2008($6.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Oragenics (NYSEAMERICAN:OGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oragenics (NYSEAMERICAN OGEN) Insider Trading and Institutional Ownership History

Insider Trading History for Oragenics (NYSEAMERICAN:OGEN)

Oragenics (NYSEAMERICAN OGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2016Randal J KirkMajor ShareholderBuy2,261,419$0.52$1,175,937.88View SEC Filing  
12/12/2014Family Lp KoskiMajor ShareholderBuy18,686$0.81$15,135.66View SEC Filing  
12/11/2014Family Lp KoskiMajor ShareholderBuy13,000$0.85$11,050.00View SEC Filing  
12/10/2014Family Lp KoskiMajor ShareholderBuy5,800$0.89$5,162.00View SEC Filing  
12/3/2014Family Lp KoskiMajor ShareholderBuy8,800$0.89$7,832.00View SEC Filing  
12/1/2014Family Lp KoskiMajor ShareholderBuy15,000$0.93$13,950.00View SEC Filing  
11/25/2014Family Lp KoskiMajor ShareholderBuy2,200$0.92$2,024.00View SEC Filing  
11/24/2014Family Lp KoskiMajor ShareholderBuy2,800$0.95$2,660.00View SEC Filing  
11/19/2014Family Lp KoskiMajor ShareholderBuy24,546$0.85$20,864.10View SEC Filing  
11/14/2014Fred TellingDirectorBuy27,000$0.95$25,650.00View SEC Filing  
11/13/2014Family Lp KoskiMajor ShareholderBuy13,000$0.84$10,920.00View SEC Filing  
11/12/2014Family Lp KoskiMajor ShareholderBuy15,100$0.85$12,835.00View SEC Filing  
11/11/2014Family Lp KoskiMajor ShareholderBuy7,000$0.85$5,950.00View SEC Filing  
8/13/2014John N BonfiglioCEOBuy1,000$1.70$1,700.00View SEC Filing  
3/26/2014Alan W DuntonDirectorSell12,000$3.02$36,240.00View SEC Filing  
3/26/2014Family Lp KoskiMajor ShareholderSell6,730$3.07$20,661.10View SEC Filing  
3/20/2014Alan W DuntonDirectorSell2,000$3.03$6,060.00View SEC Filing  
3/14/2014Family Lp KoskiMajor ShareholderSell8,009$3.11$24,907.99View SEC Filing  
3/12/2014Family Lp KoskiMajor ShareholderSell9,067$3.12$28,289.04View SEC Filing  
3/11/2014Alan W DuntonDirectorSell2,375$3.37$8,003.75View SEC Filing  
12/30/2013Alan W DuntonDirectorSell10,000$2.85$28,500.00View SEC Filing  
12/23/2013Alan W DuntonDirectorSell5,000$2.91$14,550.00View SEC Filing  
12/20/2013Alan W DuntonDirectorSell10,000$2.86$28,600.00View SEC Filing  
12/18/2013Alan W DuntonDirectorSell9,000$2.83$25,470.00View SEC Filing  
12/13/2013Alan W DuntonDirectorSell7,000$3.00$21,000.00View SEC Filing  
12/11/2013Alan W DuntonDirectorSell6,000$3.04$18,240.00View SEC Filing  
12/3/2013Charles L PopeDirectorSell10,000$3.11$31,100.00View SEC Filing  
11/20/2013Randal J KirkMajor ShareholderBuy1,242,490$2.50$3,106,225.00View SEC Filing  
9/30/2013Randal J KirkMajor ShareholderBuy2,648,510$3.00$7,945,530.00View SEC Filing  
(Data available from 1/1/2013 forward)


Oragenics (NYSEAMERICAN OGEN) News Headlines

Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?Who Are The Top Investors In Oragenics Inc (NYSEMKT:OGEN)?
finance.yahoo.com - April 21 at 9:29 AM
Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?Does Oragenics Inc (NYSEMKT:OGEN) Fall With The Market?
finance.yahoo.com - April 13 at 4:20 PM
Oragenics (OGEN) Rating Increased to Sell at ValuEngineOragenics (OGEN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 8 at 7:34 PM
BRIEF-Oragenics Announces Pricing Of $1.8 Million Registered Direct OfferingBRIEF-Oragenics Announces Pricing Of $1.8 Million Registered Direct Offering
www.reuters.com - April 6 at 4:31 PM
Oragenics prices 900K-share placement; gains down to 23%Oragenics prices 900K-share placement; gains down to 23%
seekingalpha.com - April 6 at 4:31 PM
Oragenics (OGEN) Prices $1.8 Million Registered Direct OfferingOragenics (OGEN) Prices $1.8 Million Registered Direct Offering
www.streetinsider.com - April 6 at 4:31 PM
Oragenics, Inc. Announces Pricing of $1.8 Million Registered Direct OfferingOragenics, Inc. Announces Pricing of $1.8 Million Registered Direct Offering
finance.yahoo.com - April 6 at 4:31 PM
Oragenics bucks markets sour mood, up 38%Oragenics bucks market's sour mood, up 38%
seekingalpha.com - April 6 at 10:09 AM
Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral MucositisOragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis
finance.yahoo.com - March 24 at 10:02 AM
Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?Did Oragenics Inc’s (NYSEMKT:OGEN) Earnings Growth Outperform The Industry?
finance.yahoo.com - March 12 at 5:21 PM
Oragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex HouseOragenics, Inc. to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House
finance.yahoo.com - March 6 at 4:40 PM
Oragenics Inc (OGEN) Short Interest UpdateOragenics Inc (OGEN) Short Interest Update
www.americanbankingnews.com - February 28 at 1:56 AM
Oragenics Inc (OGEN) Sees Significant Drop in Short InterestOragenics Inc (OGEN) Sees Significant Drop in Short Interest
www.americanbankingnews.com - February 9 at 6:36 PM
LKA Gold Insiders Continue to Accumulate SharesLKA Gold Insiders Continue to Accumulate Shares
finance.yahoo.com - January 29 at 4:32 PM
Oragenics Inc (OGEN) Sees Significant Increase in Short InterestOragenics Inc (OGEN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 24 at 5:40 PM
Short Interest in Oragenics Inc (OGEN) Rises By 155.3%Short Interest in Oragenics Inc (OGEN) Rises By 155.3%
www.americanbankingnews.com - January 10 at 6:04 PM
Oragenics (OGEN) Shares Scheduled to Reverse Split on Monday, January 22ndOragenics (OGEN) Shares Scheduled to Reverse Split on Monday, January 22nd
www.americanbankingnews.com - January 10 at 1:04 AM
Oragenics, Inc. Announces Reverse Stock SplitOragenics, Inc. Announces Reverse Stock Split
finance.yahoo.com - January 8 at 10:18 AM
Oragenics Inc (OGEN) Short Interest Up 195.8% in DecemberOragenics Inc (OGEN) Short Interest Up 195.8% in December
www.americanbankingnews.com - December 27 at 7:24 PM
Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry?Oragenics Inc (OGEN) Earnings: Did It Outperform The Industry?
finance.yahoo.com - November 28 at 10:27 AM
Oragenics, Inc. Regains Compliance with NYSE American Continued Listing StandardsOragenics, Inc. Regains Compliance with NYSE American Continued Listing Standards
finance.yahoo.com - November 14 at 6:29 AM

SEC Filings


This page is loading this company's SEC Filings. Please wait...

Social Media


Oragenics (NYSEAMERICAN:OGEN) Income Statement, Balance Sheet and Cash Flow Statement


Oragenics (NYSEAMERICAN OGEN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.